In the analysis RCC1/SNHG3/SNHG12 as a signature for drug-target response difference and association in pan-cancer, Topotecan, TKI258 and Paclitaxal were found which showed significant differences in different expression levels (Figures 9I,J). Here, SNHG12 is linked to cancer.